65,437 trials
Cirrhosis · Hepatitis B · Hepatitis C
Primary: Diagnosis Performance of VCTE for Determination of Cirrhosis (Metavir F4) in Patients With Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) — 0.92 ROC area
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle — 53; 44; 26; 31 participants
Erectile Dysfunction
Primary: Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious) — 33.8; 35.9 Percentage of participants
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24 — 89.52; 33.68 Percentage of participants — p=<.0001
Acute Coronary Syndrome
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 97; 138; 131; 269 Participants
Diabetes Mellitus, Type 2
Primary: HbA1c Change — -0.42; -0.58; -1.04; -1.59 absolute change in %HbA1c
Influenza
Primary: Demonstrate That the Immunogenicity of Adjuvanted Panblok H7 rHA is Sufficient to Support Emergency Use Authorization in the Event of a Declared Pandemic. — 11; 9; 15; 1…
Urinary Tract Infection Complicated · Acute Pyelonephritis
Primary: Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit…
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Primary: Tumor Response (Change) — 6.0; 3.9 cm
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Safety and Toxicity of Erlotinib Hydrochloride and Docetaxel as Measured by NCI CTC v3.0 on Day 8 of Course 1 and on Day 1 of Every Subsequent Course (Phase I [Completed…
Egg Allergy
Primary: Categorical Reactivity to Vaccine as it Was Administered — 17; 14; 3; 4 Participants
Lupus Erythematosus, Systemic
Primary: Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as Baseline — 57.8; 53.8; 44.0 percentage…
Bariatric Surgical Pain
Primary: Postoperative Pain — 3; 4.5; 8; 8 units on a scale
Pain
Primary: Time Until Analgesic Failure — 76.3; 79 Days
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation